Public record
Cyanocobalamin: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Label
FDA label facts for cyanocobalamin
The FDA label read for cyanocobalamin (Nascobal, application NDA021642) was last revised on 2024-03-01. It carries no boxed warning. Of the 4 population sections checked, 4 are present: pregnancy, lactation, pediatric use, geriatric use.
| Measure | Value | Note |
|---|---|---|
| Label revision date | 2024-03-01 | |
| Label read | Nascobal | NDA021642, brand-name application |
| Boxed warning | No | |
| Pregnancy section | Present | |
| Lactation section | Present | |
| Pediatric use section | Present | |
| Geriatric use section | Present |
How this was calculated
Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.
One label: the newest prescription label for single-ingredient cyanocobalamin from an original manufacturer
Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.
Adverse event reports
Most reported events in FDA adverse event reports for cyanocobalamin
Through 2026-10-28, FDA had received 140,554 adverse event reports for cyanocobalamin, 88,451 of them marked serious by the reporter. The symptom terms named most often were fatigue (14,606), diarrhoea (10,310) and nausea (10,285).
| Measure | Value | Note |
|---|---|---|
| All reports received | 140,554 | |
| Reports the reporter marked serious | 88,451 | death, hospitalisation, disability or similar outcome |
| Fatigue | 14,606 reports | |
| Diarrhoea | 10,310 reports | |
| Nausea | 10,285 reports | |
| Headache | 8,934 reports | |
| Pain | 7,779 reports |
How this was calculated
Counted FAERS reports listing this active substance, then the reaction terms named most often. A report can name several reactions, and a term can describe the illness being treated and not an effect of the drug. Terms about product use or complaints rather than symptoms (for example off label use) were left out of the list.
Reports where FDA recorded cyanocobalamin as a single-ingredient active substance (any brand), all years to 2026-10-28
FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs.